ANTICANCER PROPERTY STUDIES OF CHIRAL PALLADIUM N-HETEROCYCLIC CARBENE COMPLEXES AND PROCESS FOR PREPARATION THEREOF
申请人:Indian Institute of Technology Bombay
公开号:US20180194789A1
公开(公告)日:2018-07-12
The present invention relates to the anticancer property studies of a series of chiral palladium N-heterocyclic carbene complexes of the general formula of (NHC)
2
PdX
2
[NHC=chiral N-heterocyclic carbene ligand 1-(1S,2S,5R/1R,2R,5S)-menthyl-4-(R)-1,2,4-triazol-5-ylidene, wherein R=Et, allyl and CH
2
Ph; X=Br or OCOCF
3
], as designated by, (1S,2S,5R)-(1-3)b and (1R,2R,5S)-(1-3)b, (1S,2S,5R)-(1, 3)c and (1R,2R,5S)-(1, 3)c represented by formula (Ig, Ih) below.
The present invention further investigates the influence of chirality on the anticancer activity, wherein the enantiomeric pairs of present chiral palladium N-heterocyclic carbene complexes of formula (Ig, Ih) shows no differential activity based on optical isomerism despite all of the palladium complexes exhibiting high anti-proliferative activity towards a variety of cancer cells. Also, provided herein is a process of preparation of the chiral palladium N-heterocyclic carbene complexes and a pharmaceutical composition comprising the chiral palladium N-heterocyclic carbene complexes. The present invention relates to the mechanistic details highlighting the mode of action of the chiral palladium N-heterocyclic carbene complex of the formulation for their anticancer application.
本发明涉及一系列手性钯N-杂环卡宾配合物的抗癌性能研究,其一般公式为(NHC)2PdX2[NHC=手性N-杂环卡宾配体1-(1S,2S,5R/1R,2R,5S)-薄荷基-4-(R)-1,2,4-三唑-5-亚甲基,其中R=Et、烯丙基和CH2Ph;X=Br或OCOCF3],如(1S,2S,5R)-(1-3)b和(1R,2R,5S)-(1-3)b,(1S,2S,5R)-(1,3)c和(1R,2R,5S)-(1,3)c由下面的公式(Ig, Ih)表示。本发明进一步研究了手性对抗癌活性的影响,其中公式(Ig, Ih)的手性钯N-杂环卡宾配合物的对映体对显示出基于光学异构体的差异活性,尽管所有的钯配合物对多种癌细胞表现出高抗增殖活性。此外,本发明还提供了一种制备手性钯N-杂环卡宾配合物的方法和包含该手性钯N-杂环卡宾配合物的制药组合物。本发明涉及强调手性钯N-杂环卡宾配合物的作用机制细节,用于其抗癌应用。